Effective Management of Carbapenem-Resistant Enterobacterales Bloodstream Infection with Organ Dissemination in Prolonged Severe Agranulocytosis Patients with Hematological Malignancy Through Combination Therapies Including Eravacycline.

IF 5.3 3区医学 Q1 INFECTIOUS DISEASES

Infectious Diseases and Therapy Pub Date : 2025-10-01 Epub Date: 2025-08-28 DOI:10.1007/s40121-025-01206-2

Yuyuan Lv, Xin Zhang, Qingya Cui, Mengyun Li, Lian Bai, Yan Yu, XueKai Li, Xiaoqian Chen, Depei Wu, Xiaowen Tang

引用次数: 0

Abstract

This study reports three patients with hematologic malignancy patients and Carbapenem-resistant Enterobacterales (CRE) bloodstream infections and organ dissemination during neutropenia. After failed conventional therapy, a novel "through Combination therapies including eravacycline" regimen achieved fever control within 10 days and lesion resolution by 20 days approximately, demonstrating breakthrough efficacy for CRE bacteremia management.

查看原文本刊更多论文

包括依拉瓦环素在内的联合治疗对长期严重粒细胞缺乏症合并恶性血液病患者耐碳青霉烯肠杆菌血流感染伴器官播散的有效管理。

本研究报告了中性粒细胞减少期间3例血液恶性肿瘤患者和碳青霉烯耐药肠杆菌（CRE）血流感染和器官传播。在常规治疗失败后，一种新的“通过包括依拉瓦环素在内的联合治疗”方案在10天内实现了发热控制，大约20天内病变消退，显示了CRE菌血症治疗的突破性疗效。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Infectious Diseases and Therapy Medicine-Microbiology (medical)

CiteScore

8.60

自引率

1.90%

发文量

136

审稿时长

6 weeks

期刊介绍： Infectious Diseases and Therapy is an international, open access, peer-reviewed, rapid publication journal dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of infectious disease therapies and interventions, including vaccines and devices. Studies relating to diagnostic products and diagnosis, pharmacoeconomics, public health, epidemiology, quality of life, and patient care, management, and education are also encouraged. Areas of focus include, but are not limited to, bacterial and fungal infections, viral infections (including HIV/AIDS and hepatitis), parasitological diseases, tuberculosis and other mycobacterial diseases, vaccinations and other interventions, and drug-resistance, chronic infections, epidemiology and tropical, emergent, pediatric, dermal and sexually-transmitted diseases.